孟鲁司特治疗小儿过敏性紫癜(HSP)的临床疗效及对补体、C反应蛋白的影响分析  

Clinical Efficacy of Montelukast In Treatment of Children with Henoch Schonlein Purpura(HSP) and its Effect Complement and C-reactive Protein

作　　者：杨琳东 王秀萍[1] 

机构地区：[1]陕西省延安市人民医院儿科,延安716000

出　　处：《中国医药导刊》2017年第5期509-510,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:分析盂鲁司特治疗小儿过敏性紫癜(HSP)的临床疗效及对补体、C反应蛋白水平的影响。方法:选择我院2012年3月~2016年5月收治的过敏性紫癜患儿110例作为本次的研究对象,其中常规组与实验组患儿分别为55例。对常规组患儿采取基础治疗方案,实验组加用孟鲁司特治疗。结果:实验组与常规组患儿的治疗总有效率分别为96.36%与81.82%,P<0.05;治疗前两组患儿的补体与C反应蛋白水平无明显差异,P>0.05,治疗后实验组患儿上述指标改善程度明显优于常规组,P<0.05;治疗后实验组患儿临床症状与体征消失时间均明显短于常规组,P<0.05。结论:对小儿过敏性紫癜采取孟鲁司特治疗的临床疗效显著,可有效改善患儿临床症状。Objective：To analyze the montelukast treatment of Henoch Schonlein Purpura（HSP） clinical curative effect and complement,c-reactive protein level.Methods：Select our hospital in March 2012 ～ May 2016 children with HSP treated 110 cases as the research object,the normal group and experimental group of children,occupying 55 cases.Based treatment on children with nornal group,the experimental group used montelukast treatment.Results：The experimental group and routine group infants total effective rate was 96.36% and 81.82 % respectively,P 〈 0.05;Treatment of the former two groups of children with no difference between the complement and the level of c-reactive protein,P 〉 0.05,the experimental group after treatment with the above index improved significantly better than the conventional group,P 〈 0.05;The experimental group after treatmnent in children with clinical symptoms and signs disappeared time were significantly shorter in the conventional group,P 〈 0.05.Conclusion：To adopt children HSPmontelukast treatment of clinical curative effect is distinct,can effectively improve the clinical symptoms.

关 键 词：小儿 过敏性紫癜 孟鲁司特 补体 C反应蛋白 

分 类 号：R725.5[医药卫生—儿科] R554.6[医药卫生—临床医学]